Antony Waste Handling Cell Ltd Share Price – NSE  / BSE

Miscellaneous, Small Cap

On a consolidated basis, net profit of Antony Waste Handling Cell declined 56.24% to Rs 12.09 crore on 1.35% fall in net sales to Rs 221.24 crore in Q2 September 2024 over September 2023. Profit before tax stood at Rs 19.1 crore in Q2FY25, down 50% YoY and 25% QoQ.

EBITDA was at Rs 48.5 crore during the quarter, down 14% YoY and 12% QoQ. EBITDA margin were at 21.4% in Q2FY25, lower than 24.6% in the same quarter last year and 23.8% in Q1FY25.

Revenue from Municipal Solid Waste (MSW) Collection and Transportation (C&T) stood at Rs 140.9 crore in Q2FY25, down 8% YoY. but up 3% QoQ. Revenue from MSW Processing was at Rs 59.1 crore in Q2FY25, up 22% YoY. but down 4% QoQ. Sales of Refuse Derived Fuel (RDF) for Q2FY25 grew by 5% reaching ~30,500 tonnes with gradual increase from the previous year's ~29,000 tonnes.

Net cash flow from operating activities declined to Rs 69.20 crore in Q2FY25 from a cash flow of Rs 91.01 crore in Q2FY24.

Antony Waste Handling Cell is a leading Indian company specializing in Municipal Solid Waste Management (MSWM). With over two decades of experience, the company offers comprehensive MSW services including collection, transportation, processing, and disposal. They are a pioneer in MSW collection and transportation and a key player in landfill construction and management. The company is also focusing on emerging areas like waste-to-energy. They operate India's largest single-location waste processing plant in Kanjurmarg, Mumbai, and Maharashtra's first waste-to-energy plant in PCMC.

Powered by Capital Market - Live News

Net profit of Antony Waste Handling Cell declined 56.24% to Rs 12.09 crore in the quarter ended September 2024 as against Rs 27.63 crore during the previous quarter ended September 2023. Sales declined 1.35% to Rs 221.24 crore in the quarter ended September 2024 as against Rs 224.26 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Antony Waste Handling Cell will hold a meeting of the Board of Directors of the Company on 9 November 2024.

Powered by Capital Market - Live News

The headline equity indices traded near the flat line with some negative bias in mid-afternoon trade. The Nifty traded near the 25,050 mark. Pharma shares extended losses for the second consecutive trading session.

At 14:30 IST, the barometer index, the S&P BSE Sensex, was down 30.55 points or 0.03% to 81,547.06. The Nifty 50 index shed 7 points or 0.03% to 25,050.35.

In the broader market, the S&P BSE Mid-Cap index fell 0.10% and the S&P BSE Small-Cap index rose 0.06%.

The market breadth was negative. On the BSE, 1,948 shares rose and 1,967 shares fell. A total of 108 shares were unchanged.

Buzzing Index:

The Nifty Pharma index fell 0.65% to 23,403.50. The index declined 1.67% in two trading sessions.

Zydus Lifesciences (down 4.44%), Ipca Laboratories (down 3.48%), Lupin (down 2.62%), Alkem Laboratories (down 2.34%), Biocon (down 1.9%), Mankind Pharma (down 1.69%), Glenmark Pharmaceuticals (down 1.17%), Laurus Labs (down 1.14%), Cipla (down 0.8%) and J B Chemicals & Pharmaceuticals (down 0.65%) edged lower.

On the other hand, Dr Reddy's Laboratories (up 1.5%), Ajanta Pharma (up 0.91%) and Granules India (up 0.73%) edged higher.

Numbers to Track:

The yield on India's 10-year benchmark federal paper advanced 1.60% to 6.877 as compared with previous close 6.880.

In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 84.0475, compared with its close of 84.0425 during the previous trading session.

MCX Gold futures for 5 December 2024 settlement rose 0.44% to Rs 76,697.

The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.12% to 103.39.

The United States 10-year bond yield slipped 0.62% to 4.010.

In the commodities market, Brent crude for November 2024 settlement lost 13 cents or 0.18% to $74.12 a barrel.

Stocks in spotlight:

Antony Waste Handling Cell rallied 5.20% after the company informed that it has reported continued and consistent performance in Q2 & H1 FY25.

Strides Pharma Science jumped 4.35% after the firm said that its associate company, OneSource Specialty Pharma received commitment for raising Rs 801 crore ($95 million) from investors, in the pre-listing round.

Powered by Capital Market - Live News